ACTRN12617000106336已完成2 期
A Phase II trial of durvalumab (Medi 4736) in advanced endometrial cancerA multi-centre Phase II trial to determine the activity and safety of durvalumab in advanced endometrial cancer
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 71
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- Female
入选标准
- •Patients with advanced endometrial carcinoma suitable for chemotherapy
- •Adults, aged 18 years and older, with histologically or cytologically confirmed adenocarcinoma of endometrial origin
- •Advanced or recurrent disease that is not amenable to local therapy with curative intent such as surgical resection and/or radiotherapy
- •Assessment result for DNA mismatch repair (MMR) protein expression in tumour tissue by immunohistochemistry (IHC) must be available. This must include assessment for 4 MMR proteins: MLH1, MSH2, MSH6 and PMS2
- •Tumour tissue (FFPE) available for PD-L1 testing at a central laboratory
- •Agreement to undergo a repeat core biopsy of tumour tissue if the only available tumour tissue sample was obtained before previous chemotherapy or more than 1 year previously, and the investigator judges that the lesion can be biopsied without undue risk.
- •At least 1 target lesion according to RECIST v1.1
- •ECOG performance status of 0-2
- •Adequate bone marrow, renal and liver function
- •Willing and able to start treatment within 7 days of registration and to comply with all study requirements, including the timing and/or nature of the required treatment and assessments
排除标准
- •Suspected brain or leptomeningeal metastases, untreated brain metastases or current clinical or radiological progression of known brain metastases, or requirement for steroid therapy for brain metastases. Patients with treated brain metastases are eligible if they have been stable and off steroids for 3 weeks or longer.
- •Prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks before registration, or persisting adverse events (>Grade 1) due to a previously administered agent.
- •Any condition requiring systemic treatment with either corticosteroids (>10mg daily prednisone or equivalent dose of alternative corticosteroid) or other immunosuppressive medications within 28 days of durvalumab administration. Intranasal, inhaled or topical steroids are permitted in the absence of active autoimmune disease.
- •History of any known or suspected autoimmune disease other than vitiligo, type 1 diabetes mellitus, residual hypothyroidism due to an autoimmune condition requiring only hormone replacement, or psoriasis not requiring systemic treatment within the last 2 years.
- •Prior allogeneic organ transplant, inflammatory bowel disease, pneumonitis, tuberculosis, or primary immunodeficiency.
- •Prior treatment with durvalumab, or with any other anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody or any other antibody or drug specifically targeting T cell co-stimulation or immune checkpoint pathways.
- •Life expectancy of less than 12 weeks.
- •Systemic infection requiring IV antibiotics within 14 days before the first dose of durvalumab.
- •Receipt of live attenuated vaccination within 30 days prior to enrolment.
- •Known history of interstitial lung disease from any cause
- •Mean QT interval corrected for heart rate (QTc) greater than or equal to 470 ms calculated from 3 electrocardiograms (ECGs) using Fredericia's Correction
- •Myocardial infarction with 6 months prior to enrolment or New York Heart Association (NYHA) Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia, or active conduction system abnormalities.
- •History of another malignancy within 3 years prior to registration. Patients with a past history of adequately treated carcinoma-in-situ, basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or superficial transitional cell carcinoma of the bladder are eligible. Patients with a history of other malignancies are eligible if they have been continuously disease free for at least 3 years after definitive primary treatment.
- •Significant infection, including chronic active hepatitis B, hepatitis C, or HIV.
- •Serious medical or psychiatric conditions that might limit the ability of the patient to comply with the protocol.
- •Pregnancy, lactation, or inadequate contraception. Participants must be post-menopausal, infertile, or use a reliable means of contraception. Women of childbearing potential must have a negative pregnancy test done within 7 days prior to registration.
研究者
相似试验
进行中（未招募）
1 期
Treatment of patients with HIV-1 and advanced solid tumors with Durvalumabadvanced solid tumors in HIV-1 infected patientsEUCTR2016-004524-38-ESSpanish Lung Cancer Group (Grupo Español de Cáncer de Pulmón)20
进行中（未招募）
2 期
A Phase II study of Durvalumab (MEDI4736) plus carboplatin and etoposide in elderly patients with extensive-stage small-cell lung cancerextensive-stage small cell lung cancerJPRN-jRCTs071210050Koichi Azuma40
招募中
2 期
Phase II study of Durvalumab (MEDI4736) plus Total Neoadjuvant Therapy (TNT) in locally advanced rectal cancer (The DUREC trial)2024-515240-24-00Grupo Espanol Multidisciplinar En Cancer Digestivo60
进行中（未招募）
1 期
A study trying to find out if a combination of Durvalumab and Tremelimumab is more effective than doxorubicin in patients with advanced or metastatic soft tissue sarcoma.EUCTR2016-004750-15-DEAIO-Studien-gGmbH100
已完成
2 期
on small cell lung cancer trial of durvalumab and tremelimumab in advanced epidermal growth factor receptor (EGFR) mutant disease.EGFR mutant advanced non small cell lung cancer.Cancer - Lung - Non small cellACTRN12618001742268niversity of Sydney100